First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series

Table 2 Adverse events according to Common Terminology Criteria for Adverse Events (version 4.0)

Adverse event	Grade 1/2, n (%)	Grade 3, n (%)
Fatigue	24 (50.0)
Diarrhea	15 (31.3)	2 (4.2)
Mucositis	9 (18.8)
Hypertransaminasemia	7 (14.6)	4 (8.3)
Thrombocytopenia	6 (12.5)
Anemia	15 (31.2)	2 (4.2)
Neutropenia	5 (10.4)
Hypothyroidism	15 (31.3)
Disgeusia	5 (10.4)	1 (2.1)
Cutaneous toxicity1	8 (16.7)
Nausea/vomiting	14 (29.2)
Heart failure	1 (2.1)
Renal failure	5 (10.4)	1 (2.1)
Other2	16 (33.3)

¹Including discoloration of hairs and cutis, hand-foot syndrome, and dermatitis.

²Including bleeding, sleepiness, hypertrigliceridemia, hypophosphoremia, hyperbilirubinemia, loss of appetite/hyporexia, dyspepsia/epigastralgia, and hypertension.